Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications
暂无分享,去创建一个
Harald H. H. W. Schmidt | K. Krause | A. Cuadrado | P. Ghezzi | H. Schmidt | R. Stocker | A. Daiber | Manuela G. López | V. Jaquet | N. Kaludercic | F. Di Lisa | S. Leach | G. Maghzal | T. Seredenina | V. Dao | A. I. Casas | Harald H.H.W. Schmidt | Ana I Casas | Karl H. Krause | Manuela G. López | H. Schmidt
[1] A. Cuadrado,et al. Antioxidants in Translational Medicine , 2015, Antioxidants & redox signaling.
[2] Tilman Grune,et al. Clinical Relevance of Biomarkers of Oxidative Stress , 2015, Antioxidants & redox signaling.
[3] R. Fryer,et al. A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat , 2015, BMC Pharmacology and Toxicology.
[4] H. Schmidt,et al. Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. , 2015, Antioxidants & redox signaling.
[5] K. Anstrom,et al. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study , 2015, Circulation.
[6] A. Majeed,et al. Zinc: indications in brain disorders , 2015, Fundamental & clinical pharmacology.
[7] J. Stasch,et al. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. , 2015, Current opinion in pharmacology.
[8] Raynoo Thanan,et al. Oxidative Stress and Its Significant Roles in Neurodegenerative Diseases and Cancer , 2014, International journal of molecular sciences.
[9] F. StoverJohn,et al. Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). , 2014 .
[10] Sanjiv J. Shah,et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) , 2014, European journal of heart failure.
[11] N. Kaludercic,et al. Reactive oxygen species and redox compartmentalization , 2014, Front. Physiol..
[12] N. Kaludercic,et al. Monoamine oxidases as sources of oxidants in the heart. , 2014, Journal of molecular and cellular cardiology.
[13] J. Lambeth,et al. Nox4: A Hydrogen Peroxide-Generating Oxygen Sensor , 2014, Biochemistry.
[14] Chun-Peng Liao,et al. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. , 2014, The Journal of clinical investigation.
[15] R. Touyz,et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. , 2014, Antioxidants & redox signaling.
[16] R. Touyz,et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.
[17] N. Chandel,et al. ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.
[18] V. Thannickal,et al. Reversal of Persistent Fibrosis in Aging by Targeting Nox4-Nrf2 Redox Imbalance , 2014, Science Translational Medicine.
[19] T. Münzel,et al. Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. , 2014, Antioxidants & redox signaling.
[20] D. Kass,et al. Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. , 2014, Antioxidants & redox signaling.
[21] T. Ferguson,et al. Monoamine Oxidase is a Major Determinant of Redox Balance in Human Atrial Myocardium and is Associated With Postoperative Atrial Fibrillation , 2014, Journal of the American Heart Association.
[22] Y. Nakabeppu,et al. Mice Heterozygous for the Xanthine Oxidoreductase Gene Facilitate Lipid Accumulation in Adipocytes , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[23] J. Bressler,et al. Interaction between the NOS3 Gene and Obesity as a Determinant of Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study , 2013, PloS one.
[24] L. Hofbauer,et al. NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. , 2013, The Journal of clinical investigation.
[25] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[26] Richard F. Thompson,et al. Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice , 2013, Proceedings of the National Academy of Sciences.
[27] R. Brandes,et al. Monoamine Oxidases Are Mediators of Endothelial Dysfunction in the Mouse Aorta , 2013, Hypertension.
[28] E. Morand,et al. Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function. , 2013, Blood.
[29] H. Schmidt,et al. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. , 2013, Antioxidants & redox signaling.
[30] K. Andrews,et al. NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis , 2013, Circulation.
[31] Eva Dizin,et al. NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. , 2012, Journal of the American Society of Nephrology : JASN.
[32] H. Schmidt,et al. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury , 2012, Journal of Molecular Medicine.
[33] R. Ramsay. Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery. , 2012, Current topics in medicinal chemistry.
[34] Steve D. M. Brown,et al. A Mouse Model of Early-Onset Renal Failure Due to a Xanthine Dehydrogenase Nonsense Mutation , 2012, PloS one.
[35] G. Filippatos,et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes , 2012, European journal of heart failure.
[36] M. Rodríguez-Muñoz,et al. GPCRs promote the release of zinc ions mediated by nNOS/NO and the redox transducer RGSZ2 protein. , 2012, Antioxidants & redox signaling.
[37] Oliver Jung,et al. Role of Nox4 in murine models of kidney disease. , 2012, Free radical biology & medicine.
[38] H. Neumayer,et al. Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction. , 2012, The Journal of urology.
[39] U. Förstermann,et al. Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina. , 2012, Biochemical and biophysical research communications.
[40] M. Marletta,et al. Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.
[41] H. Schmidt,et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease , 2012, Cellular and Molecular Life Sciences.
[42] C. Kleinschnitz,et al. The 1027th target candidate in stroke: Will NADPH oxidase hold up? , 2012, Experimental & Translational Stroke Medicine.
[43] D. Behm,et al. Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress , 2012, Front. Pharmacol..
[44] K. Krause,et al. NOX enzymes as drug targets , 2012, Cellular and Molecular Life Sciences.
[45] K. Krause,et al. NOX5: from basic biology to signaling and disease. , 2012, Free radical biology & medicine.
[46] S. Blankenberg,et al. Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase , 2011, Circulation.
[47] H. Neumayer,et al. Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction. , 2011, The Journal of urology.
[48] B. Hinz,et al. A key role for NOX4 in epithelial cell death during development of lung fibrosis. , 2011, Antioxidants & redox signaling.
[49] J. Monks,et al. Contribution of Xanthine Oxidoreductase to Mammary Epithelial and Breast Cancer Cell Differentiation In Part Modulates Inhibitor of Differentiation-1 , 2011, Molecular Cancer Research.
[50] M. Rodríguez-Muñoz,et al. NO-released zinc supports the simultaneous binding of Raf-1 and PKCγ cysteine-rich domains to HINT1 protein at the mu-opioid receptor. , 2011, Antioxidants & redox signaling.
[51] G. Cecchini,et al. Molecular identification of the enzyme responsible for the mitochondrial NADH‐supported ammonium‐dependent hydrogen peroxide production , 2011, FEBS letters.
[52] C. Reggiani,et al. Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. , 2010, Human molecular genetics.
[53] H. Schmidt,et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors , 2010, British journal of pharmacology.
[54] H. Fuchs,et al. Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration , 2010, PLoS biology.
[55] A. Shah,et al. Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition , 2010, Hypertension.
[56] D. Atochin,et al. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction , 2010, Pflügers Archiv - European Journal of Physiology.
[57] Sonia S Anand,et al. The impact of social determinants on cardiovascular disease. , 2010, The Canadian journal of cardiology.
[58] P. Lapchak. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? , 2010, Expert opinion on pharmacotherapy.
[59] L. Gaunt,et al. Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements , 2010, European Journal of Human Genetics.
[60] T. Meinertz,et al. Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. , 2010, International journal of cardiology.
[61] U. Förstermann,et al. Pentaerythritol Tetranitrate Improves Angiotensin II–Induced Vascular Dysfunction via Induction of Heme Oxygenase-1 , 2010, Hypertension.
[62] D. Kass,et al. Monoamine Oxidase A–Mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload , 2010, Circulation research.
[63] G. Bokoch,et al. Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases. , 2009, Antioxidants & redox signaling.
[64] D. Fulton. Nox5 and the regulation of cellular function. , 2009, Antioxidants & redox signaling.
[65] T. Leto,et al. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. , 2009, Antioxidants & redox signaling.
[66] J. Stasch,et al. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteosomal degradation , 2009, Circulation research.
[67] F. Martinez,et al. NADPH Oxidase-4 Mediates Myofibroblast Activation and Fibrogenic Responses to Lung Injury , 2009, Nature Medicine.
[68] R. Holmdahl,et al. The protective role of ROS in autoimmune disease. , 2009, Trends in immunology.
[69] F. Vanmolkot,et al. Does the Unfavorable Pharmacokinetic and Pharmacodynamic Profile of the iNOS Inhibitor GW273629 Lead to Inefficacy in Acute Migraine? , 2009, Journal of clinical pharmacology.
[70] M. Giorgio,et al. Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase , 2009, Basic Research in Cardiology.
[71] D. Harrison,et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. , 2008, Journal of the American College of Cardiology.
[72] J. Shih,et al. Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.
[73] K. Krause,et al. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase , 2008, Seminars in Immunopathology.
[74] Steven R Steinhubl,et al. Why have antioxidants failed in clinical trials? , 2008, The American journal of cardiology.
[75] Songnian Hu,et al. The monoamine oxidase B gene exhibits significant association to ADHD , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[76] R. Busse,et al. Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant , 2008, Hypertension.
[77] M. Weisskopf,et al. Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.
[78] K. Krause,et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. , 2007, The Biochemical journal.
[79] W. Seeger,et al. Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature , 2007, Circulation research.
[80] T. Kawahara,et al. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes , 2007, BMC Evolutionary Biology.
[81] L. Donahue,et al. Congenital hypothyroidism, dwarfism, and hearing impairment caused by a missense mutation in the mouse dual oxidase 2 gene, Duox2. , 2007, Molecular endocrinology.
[82] K. Krause,et al. NOX1 Deficiency Protects From Aortic Dissection in Response to Angiotensin II , 2007, Hypertension.
[83] Paul L Huang,et al. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. , 2007, Cardiovascular research.
[84] G. Opala,et al. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. , 2007, Parkinsonism & related disorders.
[85] F. Van de Werf,et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. , 2007, JAMA.
[86] Eden R Martin,et al. Family‐based case–control study of MAOA and MAOB polymorphisms in Parkinson disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[87] R. Busse,et al. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. , 2006, Free radical biology & medicine.
[88] H. Shimokawa,et al. Development of genetically engineered mice lacking all three nitric oxide synthases. , 2006, Journal of pharmacological sciences.
[89] S. Neubauer,et al. 5-Methyltetrahydrofolate Rapidly Improves Endothelial Function and Decreases Superoxide Production in Human Vessels: Effects on Vascular Tetrahydrobiopterin Availability and Endothelial Nitric Oxide Synthase Coupling , 2006, Circulation.
[90] O. V. Evgenov,et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.
[91] J. Stasch,et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.
[92] Keith F. Tipton,et al. The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.
[93] C. Sigmund,et al. Inactivation of NADPH oxidase organizer 1 Results in Severe Imbalance , 2006, Current Biology.
[94] K. Krause,et al. Decreased blood pressure in NOX1‐deficient mice , 2006, FEBS letters.
[95] E. Masini,et al. Oxidative Stress by Monoamine Oxidase Mediates Receptor-Independent Cardiomyocyte Apoptosis by Serotonin and Postischemic Myocardial Injury , 2005, Circulation.
[96] D. Sorescu,et al. NAD(P)H Oxidase 4 Mediates Transforming Growth Factor-β1–Induced Differentiation of Cardiac Fibroblasts Into Myofibroblasts , 2005, Circulation research.
[97] D. Weiss,et al. Nox1 Overexpression Potentiates Angiotensin II-Induced Hypertension and Vascular Smooth Muscle Hypertrophy in Transgenic Mice , 2005, Circulation.
[98] Masato Matsuki,et al. Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice , 2005, Circulation.
[99] Denise Lau,et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[100] U. Zabel,et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[101] A. Mattevi,et al. Structure and mechanism of monoamine oxidase. , 2004, Current medicinal chemistry.
[102] A. Segal,et al. The NADPH oxidase of professional phagocytes--prototype of the NOX electron transport chain systems. , 2004, Biochimica et biophysica acta.
[103] Mario Engelmann,et al. Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. , 2004, Nitric oxide : biology and chemistry.
[104] U. Heinzmann,et al. Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. , 2004, Genes & development.
[105] T. Münzel,et al. ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.
[106] M. Currie,et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[107] A. Parini,et al. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. , 2003, American journal of physiology. Heart and circulatory physiology.
[108] B. Hoyos,et al. Zinc Release from Protein Kinase C as the Common Event during Activation by Lipid Second Messenger or Reactive Oxygen* , 2002, The Journal of Biological Chemistry.
[109] Chunxiang Zhang,et al. Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase , 2002, Science.
[110] R. Hotchkiss,et al. Myeloperoxidase produces nitrating oxidants in vivo. , 2002, The Journal of clinical investigation.
[111] J. Stasch,et al. Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies , 2002, British journal of pharmacology.
[112] D. Bullard,et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. , 2001, The Journal of clinical investigation.
[113] D. Kass,et al. Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.
[114] K. Krause,et al. A Ca2+-activated NADPH Oxidase in Testis, Spleen, and Lymph Nodes* , 2001, The Journal of Biological Chemistry.
[115] T. Gori,et al. Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance: A Human In Vivo Study , 2001, Circulation.
[116] C. Cooper,et al. Nitric oxide synthases: structure, function and inhibition , 2001 .
[117] D. Harrison,et al. Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.
[118] T. Meinertz,et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus , 2000, Diabetologia.
[119] A. Kettle,et al. Biomarkers of myeloperoxidase-derived hypochlorous acid. , 2000, Free radical biology & medicine.
[120] E. Klann,et al. Superoxide-induced Stimulation of Protein Kinase C via Thiol Modification and Modulation of Zinc Content* , 2000, The Journal of Biological Chemistry.
[121] S. Hazen,et al. Myeloperoxidase-generated oxidants and atherosclerosis. , 2000, Free radical biology & medicine.
[122] Jing Fang,et al. Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992 , 2000 .
[123] A. Morris,et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. , 2000, Hypertension.
[124] B. Mayer,et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. , 2000, Circulation research.
[125] E. Paykel,et al. Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. , 1999, American journal of medical genetics.
[126] P. Wang,et al. Current trends in the development of nitric oxide donors. , 1999, Current pharmaceutical design.
[127] A. Kettle,et al. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. , 1998, Blood.
[128] H Ishii,et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[129] R. T. Miller,et al. Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. , 1997, Biochemistry.
[130] T. Nishino,et al. The Conversion from the Dehydrogenase Type to the Oxidase Type of Rat Liver Xanthine Dehydrogenase by Modification of Cysteine Residues with Fluorodinitrobenzene* , 1997, The Journal of Biological Chemistry.
[131] J. Zweier,et al. Direct measurement of nitric oxide generation from nitric oxide synthase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[132] J. Saura,et al. Biphasic and Region-Specific MAO-B Response to Aging in Normal Human Brain , 1997, Neurobiology of Aging.
[133] E. Paykel,et al. Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis. , 1996, Human molecular genetics.
[134] R. Murray,et al. Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. , 1995, American journal of medical genetics.
[135] R. Hille,et al. Xanthine oxidase and xanthine dehydrogenase , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[136] U. Walter,et al. NO at work , 1994, Cell.
[137] J. Heinecke,et al. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. , 1994, The Journal of biological chemistry.
[138] M. Nelen,et al. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. , 1993, Science.
[139] M. Nelen,et al. X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. , 1993, American journal of human genetics.
[140] A. Chapelle,et al. Marked Amine and Amine Metabolite Changes in Norrie Disease Patients with an X‐Chromosomal Deletion Affecting Monoamine Oxidase , 1990, Journal of neurochemistry.
[141] G. Elion,et al. The purine path to chemotherapy , 1989, In Vitro Cellular & Developmental Biology.
[142] A. Chapelle,et al. Monoamine oxidase deficiency in males with an X chromosome deletion , 1989, Neuron.
[143] J. McCord,et al. Oxygen-derived free radicals in postischemic tissue injury. , 1985, The New England journal of medicine.
[144] B. Winblad,et al. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. , 1980, Life sciences.
[145] S. Klebanoff. Oxygen metabolism and the toxic properties of phagocytes. , 1980, Annals of internal medicine.
[146] E. Chiu,et al. Platelet monoamine oxidase activity in Huntington's chorea. , 1978, Journal of neurology, neurosurgery, and psychiatry.
[147] S. Klebanoff. Myeloperoxidase-Halide-Hydrogen Peroxide Antibacterial System , 1968, Journal of bacteriology.
[148] U. Ungerstedt,et al. Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). , 2014, Journal of neurotrauma.
[149] Céline Guilbeau-Frugier,et al. p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. , 2013, Antioxidants & redox signaling.
[150] R. Touyz,et al. Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. , 2012, Basic & clinical pharmacology & toxicology.
[151] J. Shih,et al. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. , 2011, International review of neurobiology.
[152] X. Estivill,et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB , 2009, Molecular Psychiatry.
[153] K. Krause,et al. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.
[154] M. Dinauer,et al. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. , 2006, Cellular signalling.
[155] D. T. Harwood,et al. Chlorine transfer between glycine, taurine, and histamine: reaction rates and impact on cellular reactivity. , 2004, Free radical biology & medicine.
[156] W. Dröge. Free radicals in the physiological control of cell function. , 2002, Physiological reviews.
[157] V. Massey. FLAVOPROTEIN STRUCTURE AND MECHANISM , 1995 .
[158] A. Clow,et al. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase? , 1993, Advances in neurology.
[159] D. Murphy,et al. Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. , 1992, American journal of medical genetics.